TP53 and head and neck cancer: Another clinical trial has recently been conducted using adenovirus expressing p53 (Ad-p53, MultiVir) in combination with immune checkpoint inhibitors in recurrent or metastatic head and neck cancer (www.clinicaltrials.gov, NCT03544723).3 To date, a great many clinical trials have proved that it is effective enough as a wide-spectrum anticancer agent.